EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	717	514/57	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 09:52
L2	589	l1 and composition	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:04
L3	518	l2 and (dextran or starch or cellulose)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:04
L4	307	l3 and (protein or peptide or EPO or hormone or interferon of factor or calcitonin)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:04
L5	74	l4 and encapsul$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:05
L6	41	l5 and emuls$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:05

EAST Search History

L7	524	514/59	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:04
L8	431	l7 and composition	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:07
L9	372	l8 and (dextran or starch or cellulose)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:08
L10	298	l9 and (protein or peptide or EPO or hormone or interferon of factor or calcitonin)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:29
L11	69	l10 and encapsul$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:29
L12	29	l11 and emuls$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:29

EAST Search History

L13	189	536/45	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:07
L14	112	l13 and composition	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:31
L15	104	l14 and (dextran or starch or cellulose)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:33
L16	52	l15 and (protein or peptide or EPO or hormone or interferon of factor or calcitonin)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:34
L17	8	l16 and encapsul$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:34
L18	6	l17 and emuls$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:40

EAST Search History

L19	663	536/1.11	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:31
L20	444	l19 and composition	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:36
L21	277	l20 and (dextran or starch or cellulose)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:37
L22	212	l21 and (protein or peptide or EPO or hormone or interferon of factor or calcitonin)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:35
L23	57	l22 and encapsul$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:36
L24	585	536/55.1	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:35

EAST Search History

L25	405	l24 and composition	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:35
L26	330	l25 and (protein or peptide or EPO or hormone or interferon of factor or calcitonin)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:35
L27	48	l26 and encapsul$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:39
L28	3067	424/490	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:36
L29	2611	l28 and composition	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:37
L30	2088	l29 and (polysaccharide or dextran or starch or cellulose)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:37

EAST Search History

L31	1101	l30 and encapsul$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:39
L32	734	l31 and emuls$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:41
L33	521	l32 and (PEG or PEO or polyvinyl)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:42
L34	458	l33 and particles	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:47
L35	3	l34 and (oil ADJ in ADJ water)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/07/20 10:44

```
dis hist

     (FILE 'HOME' ENTERED AT 11:18:20 ON 20 JUL 2007)

     FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT,
     NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2,
     WPIFV, WPINDEX, WSCA, WTEXTILES, EMBASE, MEDLINE, BIOSIS' ENTERED AT
     11:20:12 ON 20 JUL 2007
L1       7433789 S COMPOSITION
L2        554816 S L1 AND (POLYSACHARIDE OR DEXTRAN OR STARCH OR CELLULOSE)
L3             8 S L2 AND ECAPSUL?
L4         69931 S L2 AND ENCAPSUL?
L5         55983 S L4 AND (EPO OR ERYTHROPOIETIN OR CSF OR TPA OR INTERFERON O
L6         20251 S L5 AND (PEG OR PEO OR PVP OR PVA)
L7             0 S L6 AND (SOLID(A)OIL(A)WATER(A)EMULSION)
L8         20192 S L6 AND (METHOD OR PROCESS)
L9            16 S L8 AND (PARTICLES(W)DIAMETER)
L10         7614 S L6 AND MICROSPHERE
L11         1444 S L10 AND CHITOSAN
L12         1338 S L11 AND DRUG
L13          405 S L12 AND (PREDNISOLONE OR CORTISONE)
L14          236 S L13 AND (CELLULOSE(A)ACETATE)
L15          181 S L14 AND (SUSTAINED(A)RELEASE)
L16           83 S L15 AND (AQUEOUS(W) SUSPENSION)

     FILE 'CAPLUS' ENTERED AT 11:52:04 ON 20 JUL 2007
L17           36 S JIN TUO/AU
L18            2 S L17 AND ENCAPSUL?
L19          198 S ZHU HUA/AU
L20            1 S L19 AND ENCAPSUL?
L21            4 S ZHU JIAHAO/AU
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3	MAR 16	CASREACT coverage extended
NEWS 4	MAR 20	MARPAT now updated daily
NEWS 5	MAR 22	LWPI reloaded
NEWS 6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 12	MAY 01	New CAS web site launched
NEWS 13	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 17	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 18	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20	JUN 29	STN Viewer now available
NEWS 21	JUN 29	STN Express, Version 8.2, now available
NEWS 22	JUL 02	LEMBASE coverage updated
NEWS 23	JUL 02	LMEDLINE coverage updated
NEWS 24	JUL 02	SCISEARCH enhanced with complete author names
NEWS 25	JUL 02	CHEMCATS accession numbers revised
NEWS 26	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 27	JUL 16	CAplus enhanced with French and German abstracts
NEWS 28	JUL 18	CA/CAplus patent coverage enhanced

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:18:20 ON 20 JUL 2007

=> file polymer embase medline biosis
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.63       0.63

FILE 'APOLLIT' ENTERED AT 11:20:12 ON 20 JUL 2007
COPYRIGHT (c) 2007 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 11:20:12 ON 20 JUL 2007
COPYRIGHT (c) 2007 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 11:20:12 ON 20 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 11:20:12 ON 20 JUL 2007
COPYRIGHT (c) 2007 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 11:20:12 ON 20 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 11:20:12 ON 20 JUL 2007
Compendex Compilation and Indexing (C) 2007
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'DISSABS' ENTERED AT 11:20:12 ON 20 JUL 2007
COPYRIGHT (C) 2007 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 11:20:12 ON 20 JUL 2007
COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 11:20:12 ON 20 JUL 2007
COPYRIGHT (C) 2007 IFI CLAIMS(R) Patent Services (IFI)

FILE 'NTIS' ENTERED AT 11:20:12 ON 20 JUL 2007
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2007)

FILE 'PASCAL' ENTERED AT 11:20:12 ON 20 JUL 2007
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2007 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 11:20:12 ON 20 JUL 2007
COPYRIGHT (C) 2007 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 11:20:12 ON 20 JUL 2007
COPYRIGHT (C) 2007 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 11:20:12 ON 20 JUL 2007
Copyright (c) 2007 The Thomson Corporation
```

```
FILE 'TEXTILETECH' ENTERED AT 11:20:12 ON 20 JUL 2007
COPYRIGHT (C) 2007 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 11:20:12 ON 20 JUL 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:20:12 ON 20 JUL 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 11:20:12 ON 20 JUL 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'WPINDEX' ENTERED AT 11:20:12 ON 20 JUL 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'WSCA' ENTERED AT 11:20:12 ON 20 JUL 2007
COPYRIGHT (C) 2007 PAINT RESEARCH

FILE 'WTEXTILES' ENTERED AT 11:20:12 ON 20 JUL 2007
COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EMBASE' ENTERED AT 11:20:12 ON 20 JUL 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 11:20:12 ON 20 JUL 2007

FILE 'BIOSIS' ENTERED AT 11:20:12 ON 20 JUL 2007
Copyright (c) 2007 The Thomson Corporation

=> s composition
  19 FILES SEARCHED...
L1     7433789 COMPOSITION

=> s l1 and (polysacharide or dextran or starch or cellulose)
  23 FILES SEARCHED...
L2      554816 L1 AND (POLYSACHARIDE OR DEXTRAN OR STARCH OR CELLULOSE)

=> s l2 and ecapsul?
L3            8 L2 AND ECAPSUL?

=> s l2 and encapsul?
L4        69931 L2 AND ENCAPSUL?

=> s l4 and (EPO or erythropoietin or CSF or TPA or interferon or hormone or
calcitonin or factor or protein or peptide)
  11 FILES SEARCHED...
  23 FILES SEARCHED...
L5        55983 L4 AND (EPO OR ERYTHROPOIETIN OR CSF OR TPA OR INTERFERON OR
                HORMONE OR CALCITONIN OR FACTOR OR PROTEIN OR PEPTIDE)

=> s l5 and (PEG or PEO or PVP or PVA)
L6        20251 L5 AND (PEG OR PEO OR PVP OR PVA)

=> s l6 and (solid(a)oil(a)water(a)emulsion)
  11 FILES SEARCHED...
L7            0 L6 AND (SOLID(A) OIL(A) WATER(A) EMULSION)

=> s l6 and (method or process)
   6 FILES SEARCHED...
  10 FILES SEARCHED...
  15 FILES SEARCHED...
L8        20192 L6 AND (METHOD OR PROCESS)
```

```
=> s l8 and (particles(w)diameter)
  22 FILES SEARCHED...
L9          16 L8 AND (PARTICLES(W) DIAMETER)

=> dis l9 1-16 bib abs

L9   ANSWER 1 OF 16  USPATFULL on STN
AN     2006:273983  USPATFULL
TI     Use of bacteriocin for the amelioration of digestive functionality
IN     Piva, Andrea, Bologna, ITALY
       Casadei, Gabriele, San Carlo Cesena (FC), ITALY
PI     US 2006233777       A1  20061019
AI     US 2004-551536      A1  20040325 (10)
       WO 2004-IB885           20040325
                               20060605  PCT 371 date
PRAI   WO 2003-IT193       20030401
DT     Utility
FS     APPLICATION
LREP   PEARNE & GORDON LLP, 1801 EAST 9TH STREET, SUITE 1200, CLEVELAND, OH,
       44114-3108, US
CLMN   Number of Claims: 14
ECL    Exemplary Claim: 1-15
DRWN   No Drawings
LN.CNT 783
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The subject of the present invention is the use of bacteriocins and/or
       their producer strains for the amelioration of digestive functionality
       and for the amelioration of gastrointestinal tract conditions in
       monogastric organism species.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9   ANSWER 2 OF 16  USPATFULL on STN
AN     2006:228410  USPATFULL
TI     Compositions and methods using same for treating
       amyloid-associated diseases
IN     Gazit, Ehud, Ramat-HaSharon, ISRAEL
       Porat, Yair, Hofit, ISRAEL
PI     US 2006194777       A1  20060831
AI     US 2006-386880      A1  20060323 (11)
RLI    Continuation-in-part of Ser. No. WO 2004-IL890, filed on 23 Sep 2004,
       UNKNOWN
DT     Utility
FS     APPLICATION
LREP   Martin D. MOYNIHAN, PRTSI, Inc., P.O. Box 16446, Arlington, VA, 22215,
       US
CLMN   Number of Claims: 34
ECL    Exemplary Claim: 1
DRWN   21 Drawing Page(s)
LN.CNT 2261
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Compounds having one or more phenol moieties, derivatives thereof,
       compositions containing same and uses thereof for the treatment
       of amyloid-associated diseases are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9   ANSWER 3 OF 16  USPATFULL on STN
AN     2006:174655  USPATFULL
TI     Detection of ion channel or receptor activity
IN     Marini, Davide, Brookline, MA, UNITED STATES
       Desai, Bimal, Arlington, MA, UNITED STATES
       Delling, Markus, Boston, MA, UNITED STATES
```

Solis, Daniel, Boston, MA, UNITED STATES
Febvay, Sebastien, Cambridge, MA, UNITED STATES
Carter, Brett, Brighton, MA, UNITED STATES
Belcher, Angela, Lexington, MA, UNITED STATES
Clapham, David, Wellesley, MA, UNITED STATES
PA Massachusetts Institute of Technology (U.S. corporation)
Children's Medical Center Corporation (U.S. corporation)
PI US 2006148104 A1 20060706
AI US 2005-264074 A1 20051031 (11)
PRAI WO 2005-US39260 20051031
US 2004-623334P 20041029 (60)
DT Utility
FS APPLICATION
LREP CHOATE, HALL & STEWART LLP, TWO INTERNATIONAL PLACE, BOSTON, MA, 02110, US
CLMN Number of Claims: 175
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 5462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides nanosensors and nanosensor components for the detection of ion channel activity, receptor activity, or protein protein interactions. Certain of the nanosensor components comprise a nanoparticle and recognition domain. Following contact with cells and, optionally, internalization of the nanosensor component by a cell, the recognition domain binds to a target domain, e.g., a heterologous target domain, of a polypeptide of interest such as an ion channel subunit, G protein coupled receptor (GPCR), or G protein subunit. Ion channel activity, GPCR activity, or altered protein interaction results in a detectable signal. The nanoparticles may be functionalized so that they respond to the presence of an ion by altering their proximity. Certain of the nanosensors utilize the phenomenon of plasmon resonance to produce a signal while others utilize magnetic properties, RET, and/or ion-sensitive moieties. Also provided are polypeptides, e.g., ion channel subunits, comprising a heterologous target domain, and cell lines that express the polypeptides. Further provided are a variety of methods for detecting ion channel activity, receptor activity, or protein interaction and for identifying compounds that modulate one or more of these. In certain embodiments the invention allows the user to detect the activity of specific ion channels even in the presence of other channels that permit passage of the same ion(s) or result in activation of the same downstream targets, thereby achieving improved specificity in high throughput screens while at the same time providing a high signal to noise ratio.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 16 USPATFULL on STN
AN 2006:166403 USPATFULL
TI Central airway administration for systemic delivery of therapeutics
IN Blumberg, Richard S., Chestnut Hill, MA, UNITED STATES
Lencer, Wayne I., Jamaica Plain, MA, UNITED STATES
Simister, Neil E., Wellesley, MA, UNITED STATES
Bitonti, Alan J., Acton, MA, UNITED STATES
PI US 2006140907 A1 20060629
AI US 2006-336581 A1 20060120 (11)
RLI Continuation of Ser. No. US 2003-435608, filed on 9 May 2003, PENDING
Continuation-in-part of Ser. No. WO 2002-US21335, filed on 3 Jul 2002, PENDING
PRAI US 2002-364482P 20020315 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,

BOSTON, MA, 02210-2206, US
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 3829
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 16 USPATFULL on STN
AN 2005:68465 USPATFULL
TI Drug delivery system based on polymer nanoshells
IN Gao, Jinming, Pepper Pike, OH, UNITED STATES
Ai, Hua, Cleveland, OH, UNITED STATES
PA Case Western Reserve University, Cleveland, OH (U.S. corporation)
PI US 2005058603 A1 20050317
AI US 2004-838289 A1 20040503 (10)
PRAI US 2003-502429P 20030912 (60)
US 2003-467389P 20030502 (60)
DT Utility
FS APPLICATION
LREP ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA, 02110-2624
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 5026
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to polymeric nanoshells. In certain embodiments, the polymeric nanoshells comprise one or more polymeric shells around a hollow core. In other embodiments, the present invention provides nanoshells useful for the delivery of agents such as, for example, various diagnostic and therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 16 USPATFULL on STN
AN 2005:66053 USPATFULL
TI Printing plate material and printing process
IN Mori, Takahiro, Tokyo, JAPAN
PA KONICA MINOLTA MEDICAL & GRAPHIC, INC. (non-U.S. corporation)
PI US 2005056179 A1 20050317
US 7107905 B2 20060919
AI US 2004-938889 A1 20040913 (10)
PRAI JP 2003-324234 20030917
DT Utility
FS APPLICATION
LREP Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1622
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a printing plate material comprising a support and provided thereon, a hydrophilic layer containing pigment particles having a light-to-heat conversion capability, wherein the pigment particles have an average particle diameter of from 0.15 μm to less than 1.0 μm, and the hydrophilic layer has a surface roughness Ra of from 0.2 μm to less than 1.5 μm.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 16 USPATFULL on STN
AN 2004:215210 USPATFULL
TI Iridescent pigment having high brilliance and high chroma
IN Noguchi, Tamio, Fukushima-ken, JAPAN
PI US 2004166316 A1 20040826
US 7241503 B2 20070710
AI US 2003-717926 A1 20031121 (10)
PRAI JP 2002-338344 20021121
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An iridescent multilayer pigment having at least two or more layers of metal oxides containing one or more metals selected from Ce, Sn, Ti, Fe, Zn and Zr which are coated onto the surface of thin platelet-like substrates. The inventive pigments show high brilliance and high chroma, in particular in cases in which thin platelet-like substrates having a fine average particle diameter are used. The pigment is useful in paints, printing inks, lacquers, plastics, dopants for laser marking, non-dusting pigment products, non-dusting pigment granules or cosmetics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 16 USPATFULL on STN
AN 2004:83456 USPATFULL
TI Central airway administration for systemic delivery of therapeutics
IN Blumberg, Richard S., Chestnut Hill, MA, UNITED STATES
Lencer, Wayne I., Jamaica Plain, MA, UNITED STATES
Simister, Neil E., Wellesley, MA, UNITED STATES
Bitonti, Alan J., Acton, MA, UNITED STATES
PA Thé Brigham and Women's Hospital, Inc., Boston, MA (U.S. corporation)
Children's Medical Center Corporation, Boston, MA (U.S. corporation)
Brandeis University, Waltham, MA (U.S. corporation)
Syntonix Pharmaceuticals, Inc., Waltham, MA (U.S. corporation)
PI US 2004063912 A1 20040401
AI US 2003-622108 A1 20030717 (10)
RLI Continuation-in-part of Ser. No. US 2003-435608, filed on 9 May 2003, PENDING Continuation-in-part of Ser. No. WO 2002-US21335, filed on 3 Jul 2002, PENDING
PRAI US 2002-364482P 20020315 (60)
DT Utility
FS APPLICATION
LREP Alan W. Steele, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 4477
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and products for the

transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. In particular embodiments the conjugates are fusion proteins in which a therapeutic polypeptide is joined at its C terminal end through a peptide linker to the N terminal end of an immunoglobulin Fc gamma heavy chain, wherein the linker includes Glycine and Serine residues and is preferably 15 amino acids long. In one embodiment the fusion protein includes an interferon-alpha 2b (IFN-α2b) joined at its C terminal end through a peptide linker having a sequence Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser (SEQ ID NO:29) to the N terminal end of a human Fcγ1 heavy chain. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 16 USPATFULL on STN
AN 2003:334661 USPATFULL
TI Central airway administration for systemic delivery of therapeutics
IN Blumberg, Richard S., Chestnut Hill, MA, UNITED STATES
Lencer, Wayne I., Jamaica Plain, MA, UNITED STATES
Simister, Neil E., Wellesley, MA, UNITED STATES
Bitonti, Alan J., Acton, MA, UNITED STATES
PA The Brigham and Women's Hospital, Inc., Boston, MA, UNITED STATES, 02115 (U.S. corporation)
Children's Medical Center Corporation, Boston, MA, UNITED STATES, 02115 (U.S. corporation)
Brandeis University, Waltham, MA, UNITED STATES, 02254 (U.S. corporation)
Syntonix Pharmaceuticals, Inc., Waltham, MA, UNITED STATES, 02451 (U.S. corporation)
PI US 2003235536 A1 20031225
AI US 2003-435608 A1 20030509 (10)
RLI Continuation-in-part of Ser. No. WO 2002-US21335, filed on 3 Jul 2002, PENDING
PRAI US 2002-364482P 20020315 (60)
DT Utility
FS APPLICATION
LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211
CLMN Number of Claims: 127
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 4042
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 16 USPATFULL on STN
AN 2003:244817 USPATFULL
TI Isotropic cleansing composition with benefit agent particles
IN Shana'a, May, Trumbull, CT, UNITED STATES
Villa, Virgilio Barba, Emerson, NJ, UNITED STATES
PA Unilever Home and Personal Care USA, Division of Conopco, Inc. (U.S. corporation)
PI US 2003171230 A1 20030911
US 6737394 B2 20040518
AI US 2002-90086 A1 20020304 (10)
DT Utility
FS APPLICATION
LREP UNILEVER, PATENT DEPARTMENT, 45 RIVER ROAD, EDGEWATER, NJ, 07020
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1478
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An aqueous isotropic liquid cleansing and moisturizing composition is provided having a surfactant; a thickening agent, and organogel particles with a structure comprising a benefit agent and a gellation agent. In a preferred embodiment the inventive cleansing composition includes a free emollient having a weight average emollient particle size in the range about 1 to about 500 microns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 16 USPATFULL on STN
AN 2002:236027 USPATFULL
TI Methods and products related to pulmonary delivery of polysaccharides
IN Liu, Dongfang, Framingham, MA, UNITED STATES
Qi, Yiwei, Framingham, MA, UNITED STATES
Venkataraman, Ganesh, Woburn, MA, UNITED STATES
Sundaram, Mallikarjun, Brighton, MA, UNITED STATES
Sasisekharan, Ram, Cambridge, MA, UNITED STATES
PA Massachusetts Institute of Technology, Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2002128225 A1 20020912
AI US 2001-982548 A1 20011018 (9)
PRAI US 2000-241559P 20001018 (60)
DT Utility
FS APPLICATION
LREP Helen C. Lockhart, Wolf, Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210
CLMN Number of Claims: 112
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2380
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to methods for delivering polysaccharides by a pulmonary route to achieve local and systemic therapeutic effects. The polysaccharides may be formulated or unformulated and in some instances have an extremely fast absorption rate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 16 USPATFULL on STN
AN 2002:119885 USPATFULL
TI Spontaneously dispersible N-benzoyl staurosporine compositions
IN Matthews, Graham Paul, Horsham, UNITED KINGDOM

Haeberlin, Barbara, Munchenstein, SWITZERLAND
PI US 2002061873 A1 20020523
AI US 2001-930335 A1 20010815 (9)
RLI Continuation of Ser. No. WO 2000-EP1196, filed on 14 Feb 2000, UNKNOWN
PRAI GB 1999-3547 19990216
DT Utility
FS APPLICATION
LREP THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 849
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Spontaneously dispersible N-benzoyl-staurosporine compositions are discussed for oral administration having high bioavailability levels and reduced variability of bioavailability levels of N-benzoyl-staurosporine, as well as their preparation and use in medical treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 16 USPAT2 on STN
AN 2005:66053 USPAT2
TI Printing plate material and printing process
IN Mori, Takahiro, Hachioji, JAPAN
PA Konica Minolta Medical & Graphic, Inc., Tokyo, JAPAN (non-U.S. corporation)
PI US 7107905 B2 20060919
AI US 2004-938889 20040913 (10)
PRAI JP 2003-324234 20030917
DT Utility
FS GRANTED
EXNAM Primary Examiner: Colilia, Daniel J.; Assistant Examiner: Culler, Jill E.
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1598
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a printing plate material comprising a support and provided thereon, a hydrophilic layer containing pigment particles having a light-to-heat conversion capability, wherein the pigment particles have an average particle diameter of from 0.15 μm to less than 1.0 μm, and the hydrophilic layer has a surface roughness Ra of from 0.2 μm to less than 1.5 μm.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 16 USPAT2 on STN
AN 2004:215210 USPAT2
TI Iridescent pigment having high brilliance and high chroma
IN Noguchi, Tamio, Fukushima-ken, JAPAN
PA Merck Patent GmbH, Darmstadt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 7241503 B2 20070710
AI US 2003-717926 20031121 (10)
PRAI JP 2002-338344 20021121
DT Utility
FS GRANTED
EXNAM Primary Examiner: Le, H. Thi
LREP Millen, White, Zelano & Branigan, P.C.
CLMN Number of Claims: 28

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1386
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An iridescent multilayer pigment having at least two or more layers of metal oxides containing one or more metals selected from Ce, Sn, Ti, Fe, Zn and Zr which are coated onto the surface of thin platelet-like substrates. The inventive pigments show high brilliance and high chroma, in particular in cases in which thin platelet-like substrates having a fine average particle diameter are used. The pigment is useful in paints, printing inks, lacquers, plastics, dopants for laser marking, non-dusting pigment products, non-dusting pigment granules or cosmetics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 16 USPAT2 on STN
AN 2004:77318 USPAT2
TI Biopolymers obtained by solid state irradiation in an unsaturated gaseous atmosphere
IN Phillips, Glyn Owen, Cardiff, UNITED KINGDOM
Du Plessis, Tjaart Andries, Pretoria, SOUTH AFRICA
Al-Assaf, Saphwan, Wrexham, UNITED KINGDOM
Williams, Peter Anthony, Cardiff, UNITED KINGDOM
PA Phillips Hydrocolloids Research Limited, London, UNITED KINGDOM (non-U.S. corporation)
PI US 6841644 B2 20050111
AI US 2003-400632 20030328 (10)
RLI Division of Ser. No. US 2001-805385, filed on 13 Mar 2001, now patented, Pat. No. US 6610810
DT Utility
FS GRANTED
EXNAM Primary Examiner: Nutter, Nathan M.
LREP Galvin & Palmer, Palmer, Sheldon
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 41 Drawing Figure(s); 25 Drawing Page(s)
LN.CNT 1416
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are modified naturally occurring biocompatible biopolymers of plant and animal origin made by subjecting same to ionizing radiation in the presence of a mediating gas, typically acetylene to enable one to selectively enhance and modify one or more of the physiochemical properties of the starting materials which have a wide range of uses in medicine, food technology and other industrial applications. Notwithstanding the modifications, the biocompatibility of the biopolymer remains unchanged and no new or additional functional groups are introduced into the starting biopolymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 16 USPAT2 on STN
AN 2003:244817 USPAT2
TI Isotropic cleansing composition with benefit agent particles
IN Shana'a, May, Trumbull, CT, United States
Villa, Virgilio Barba, Emerson, NJ, United States
PA Unilever Home & Personal Care USA, division of Conopco, Inc., Greenwich, CT, United States (U.S. corporation)
PI US 6737394 B2 20040518
AI US 2002-90086 20020304 (10)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Hardee, John R.
LREP Bornstein, Alan A.
CLMN Number of Claims: 27

ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1436
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An aqueous isotropic liquid cleansing and moisturizing composition is provided having a surfactant; a thickening agent, and organogel particles with a structure comprising a benefit agent and a gellation agent. In a preferred embodiment the inventive cleansing composition includes a free emollient having a weight average emollient particle size in the range about 1 to about 500 microns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s l6 and microsphere
L10 7614 L6 AND MICROSPHERE

=> s l10 and chitosan
L11 1444 L10 AND CHITOSAN

=> s l11 and drug
22 FILES SEARCHED...
L12 1338 L11 AND DRUG

=> s l12 and (prednisolone or cortisone)
L13 405 L12 AND (PREDNISOLONE OR CORTISONE)

=> s l13 and (cellulose(a)acetate)
L14 236 L13 AND (CELLULOSE(A) ACETATE)

=> s l14 and (sustained(a)release)
L15 181 L14 AND (SUSTAINED(A) RELEASE)

=> s l15 and (aqueous(w) suspension)
L16 83 L15 AND (AQUEOUS(W) SUSPENSION)

=> dis l16 1-83 bib abs

L16 ANSWER 1 OF 83 USPATFULL on STN
AN 2007:184697 USPATFULL
TI Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
IN Castro, Alfredo C., Winchester, MA, UNITED STATES
Holson, Edward B., Newton Highlands, MA, UNITED STATES
Hopkins, Brian T., Brookline, MA, UNITED STATES
Koney, Nii O., Brighton, MA, UNITED STATES
Snyder, Daniel A., Cambridge, MA, UNITED STATES
Tibbitts, Thomas T., Westford, MA, UNITED STATES
PA Infinity Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2007161690 A1 20070712
AI US 2006-600332 A1 20061115 (11)
RLI Continuation-in-part of Ser. No. US 2005-156364, filed on 17 Jun 2005, PENDING
PRAI US 2004-580616P 20040617 (60)
US 2005-659301P 20050307 (60)
DT Utility
FS APPLICATION
LREP FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2349

AB One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

L16 ANSWER 2 OF 83 USPATFULL on STN
AN 2007:106584 USPATFULL
TI Compositions and methods of making rapidly dissolving lonically masked formulations
IN Tengler, Mark, Colleyville, TX, UNITED STATES
McMahen, Russell Lee, Flower Mound, TX, UNITED STATES
PA PFab LP, Grand Prairie, TX, UNITED STATES (U.S. corporation)
PI US 2007092553 A1 20070426
AI US 2005-255555 A1 20051021 (11)
DT Utility
FS APPLICATION
LREP CHALKER FLORES, LLP, 2711 LBJ FRWY, Suite 1036, DALLAS, TX, 75234, US
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1851
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug -resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug in the drug resin complex relative to an otherwise identical pharmaceutical composition without the resin; and wherein the highly compressible, free-flowing pharmaceutical excipient causes release of the drug-resin complex in the mouth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 3 OF 83 USPATFULL on STN
AN 2007:62144 USPATFULL
TI Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
IN Manoharan, Muthiah, Weston, MA, UNITED STATES
Rajeev, Kallanthottathil G., Cambridge, MA, UNITED STATES
Xia, Jie, Carlsbad, CA, UNITED STATES
PA Alnylam Pharmaceuticals, Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2007054279 A1 20070308
AI US 2005-197753 A1 20050804 (11)
PRAI US 2004-598596P 20040804 (60)
DT Utility
FS APPLICATION
LREP FOLEY HOAG, LLP, PATENT GROUP (w/APX), 155 SEAPORT BLVD, BOSTON, MA, 02210-2600, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 39 Drawing Page(s)
LN.CNT 7590
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, only one of the two oligonucleotide strands

comprising the double-stranded oligonucleotide contains a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 4 OF 83 USPATFULL on STN
AN 2007:12286 USPATFULL
TI Medical device with low magnetic susceptibility
IN Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard J., Rochester, NY,. UNITED STATES
PI US 2007010702 A1 20070111
AI US 2005-171761 A1 20050630 (11)
RLI Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, GRANTED, Pat. No. US 7091412 Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, ABANDONED Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, GRANTED, Pat. No. US 6914412 Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609
DT Utility
FS APPLICATION
LREP CURATOLO SIDOTI CO., LPA, 24500 CENTER RIDGE ROAD, SUITE 280, CLEVELAND, OH, 44145, US
CLMN Number of Claims: 315
ECL Exemplary Claim: 1
DRWN 54 Drawing Page(s)
LN.CNT 18747
AB An assembly that contains a medical device and biological material within which the medical device is disposed. The assembly has a direct or alternating current magnetic susceptibility within the range of from about plus 1+10.sup.-2 centimeter-gram-seconds to about minus 1+10.sup.-2 centimeter-gram-seconds.

L16 ANSWER 5 OF 83 USPATFULL on STN
AN 2007:12087 USPATFULL
TI Methods and reagents for the treatment of immunoinflammatory disorders
IN Keith, Curtis, Boston, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Zimmermann, Grant R., Somerville, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES
Hurst, Nicole, Boston, MA, UNITED STATES
Foley, Michael A., Chestnut Hill, MA, UNITED STATES

Slavonic, Michael S., Quincy, MA, UNITED STATES
Smith, Brendan, Somerville, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
PA CombinatoRx Inc., Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2007010502 A1 20070111
AI US 2006-517593 A1 20060907 (11)
RLI Continuation of Ser. No. US 2004-966228, filed on 15 Oct 2004, PENDING
PRAI US 2003-512415P 20031015 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4260
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 6 OF 83 USPATFULL on STN
AN 2006:334645 USPATFULL
TI Oligonucleotides comprising a non-phosphate backbone linkage
IN Manoharan, Muthiah, Weston, MA, UNITED STATES
Rajeev, Kallanthottathil G., Cambridge, MA, UNITED STATES
PA Alnylam Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2006287260 A1 20061221
AI US 2005-170798 A1 20050629 (11)
PRAI US 2004-584061P 20040630 (60)
US 2004-614528P 20040930 (60)
DT Utility
FS APPLICATION
LREP FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 9371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3'-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a non-phosphate linkage occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands. In certain embodiments, a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate,

hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a ligand is bound to the oligonucleotide strand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 83 USPATFULL on STN
AN 2006:333565 USPATFULL
TI Methods and reagents for the treatment of inflammatory disorders
IN Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Nolan, Garry, Brookline, MA, UNITED STATES
Zimmermann, Grant R., Somerville, MA, UNITED STATES
PA CombinatoRx, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2006286177 A1 20061221
AI US 2006-454559 A1 20060616 (11)
PRAI US 2005-691953P 20050617 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2519
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering bufexamac and a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing bufexamac and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 83 USPATFULL on STN
AN 2006:328918 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2006282123 A1 20061214
AI US 2004-6910 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2264
DRWN 32 Drawing Page(s)
LN.CNT 14774

AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L16 ANSWER 9 OF 83 USPATFULL on STN
AN 2006:28626 USPATFULL
TI Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
IN Castro, Alfredo C., Winchester, MA, UNITED STATES
Deng, Wei, Lexington, MA, UNITED STATES
Depew, Kristopher M., Acton, MA, UNITED STATES
Foley, Michael A., Chestnut Hill, MA, UNITED STATES
Fritz, Christian C., Natick, MA, UNITED STATES
Georges Evangelinos, Asimina T., Andover, MA, UNITED STATES
Grogan, Michael J., Arlington, MA, UNITED STATES
Hafeez, Nafeeza, West Roxbury, MA, UNITED STATES
Holson, Edward B., Newton Highlands, MA, UNITED STATES
Hopkins, Brian T., Brookline, MA, UNITED STATES
Koney, Nii O., Somerville, MA, UNITED STATES
Liu, Tao, Ashland, MA, UNITED STATES
Mann, David A., Swampscott, MA, UNITED STATES
Marcaurelle, Lisa A., Arlington, MA, UNITED STATES
Snyder, Daniel A., Cambridge, MA, UNITED STATES
Underwood, Dennis J., Jamaica Plain, MA, UNITED STATES
Wylie, Andrew A., Brookline, MA, UNITED STATES
Yu, Lin-Chen, Wollaston, MA, UNITED STATES
Zhang, Linping, Lexington, MA, UNITED STATES
PA Infinity Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 2006025460 A1 20060202
AI US 2005-156364 A1 20050617 (11)
PRAI US 2004-580616P 20040617 (60)
US 2005-659301P 20050307 (60)
DT Utility
FS APPLICATION
LREP FOLEY HOAG, LLP, PATENT GROUP, WORLD TRADE CENTER WEST, 155 SEAPORT BLVD, BOSTON, MA, 02110, US
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 6924
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 10 OF 83 USPATFULL on STN
AN 2006:10579 USPATFULL
TI Nitrosated and nitrosylated compounds, compositions and methods use
IN Earl, Richard A., Westford, MA, UNITED STATES
Garvey, David S., Dover, MA, UNITED STATES
Gaston, Ricky D., Malden, MA, UNITED STATES
Lin, Chia-En, Concord, MA, UNITED STATES
Ranatunge, Ramani R., Lexington, MA, UNITED STATES
Richardson, Stewart K., Tolland, CT, UNITED STATES

Stevenson, Cheri A., Haverhill, MA, UNITED STATES
PA Nitromed, Inc., Lexington, MA, UNITED STATES (U.S. corporation)
PI US 2006009431 A1 20060112
AI US 2005-221901 A1 20050909 (11)
RLI Continuation of Ser. No. WO 2004-US7943, filed on 15 Mar 2004, PENDING
PRAI US 2003-453963P 20030313 (60)
US 2003-482134P 20030625 (60)
DT Utility
FS APPLICATION
LREP EDWARD D GRIEFF, HALE & DORR LLP, 1455 PENNSYLVANIA AVE, NW, WASHINGTON, DC, 20004, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6251
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention describes novel nitrosated and/or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and at least one nitric oxide donor compound and/or at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for inhibiting platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative or vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering at least one compound of the invention that is optionally nitrosated and/or nitrosylated, in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The compounds of the invention are preferably estradiol compounds, troglitazone compounds, tranilast compounds, retinoic acid compounds, resveratol compounds, myophenolic acid compounds, acid compounds, anthracenone compounds and trapidil compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 11 OF 83 USPATFULL on STN
AN 2005:331259 USPATFULL
TI Oligonucleotides comprising a C5-modified pyrimidine
IN Manoharan, Muthiah, Weston, MA, UNITED STATES
Rajeev, Kallanthottathil G., Cambridge, MA, UNITED STATES
PA Alnylam Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES, 02142 (U.S. corporation)
PI US 2005288244 A1 20051229
AI US 2005-119533 A1 20050429 (11)
PRAI US 2004-566710P 20040430 (60)
US 2004-620276P 20041020 (60)
DT Utility
FS APPLICATION
LREP FOLEY HOAG LLP, 155 SEAPORT BLVD - SEAPORT WORLD TRADE CENTER WEST, BOSTON, MA, 02210-2600, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 6466

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand. In certain embodiments, a ligand is bound to only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, both of the oligonucleotide strands of the double-stranded oligonucleotide independently comprise a bound ligand. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. In certain embodiments, a phosphate linkage in one or both of the strands of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5β-cholanic acid. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety. In certain embodiments, a phosphate linkage of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5β-cholanic acid. The ligand improves the pharmacokinetic properties of the oligonucleotide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 12 OF 83 USPATFULL on STN
AN 2005:318834 USPATFULL
TI Compositions and methods for treating diverticular disease
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005277577 A1 20051215
US 7241736 B2 20070710
AI US 2005-129763 A1 20050512 (11)
RLI Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 10081
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Agents, compositions, and implants are provided herein for treating diverticular disease (e.g., diverticulosis and diverticulitis). In particular, fibrosis-inducing agents, hemostatic agents, and/or anti-infective agents, or compositions containing one or more of these agents are provided for use in methods for treating diverticular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 13 OF 83 USPATFULL on STN
AN 2005:241661 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005209666 A1 20050922
AI US 2004-6885 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-630
DRWN 32 Drawing Page(s)
LN.CNT 14772
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 14 OF 83 USPATFULL on STN
AN 2005:241660 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005209665 A1 20050922
AI US 2004-998351 A1 20041126 (10)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-11691
DRWN 32 Drawing Page(s)
LN.CNT 14777
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within

an animal.

L16 ANSWER 15 OF 83 USPATFULL on STN
AN 2005:241659 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005209664 A1 20050922
AI US 2004-998349 A1 20041126 (10)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586471P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1377
DRWN 32 Drawing Page(s)
LN.CNT 14786
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L16 ANSWER 16 OF 83 USPATFULL on STN
AN 2005:240095 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005208095 A1 20050922
AI US 2004-996354 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 101

ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 34089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 17 OF 83 USPATFULL on STN
AN 2005:234693 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005203635 A1 20050915
AI US 2004-6909 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 76
ECL Exemplary Claim: 1-3038
DRWN 32 Drawing Page(s)
LN.CNT 12596
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 18 OF 83 USPATFULL on STN
AN 2005:226572 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005196421 A1 20050908
AI US 2004-1417 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 100
ECL Exemplary Claim: 1-7300
DRWN 32 Drawing Page(s)
LN.CNT 34222
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 19 OF 83 USPATFULL on STN
AN 2005:221910 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005192647 A1 20050901
AI US 2004-6898 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1992
DRWN 32 Drawing Page(s)
LN.CNT 14794
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L16 ANSWER 20 OF 83 USPATFULL on STN
AN 2005:215962 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 2005187639 A1 20050825
AI US 2004-6892 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 101
ECL Exemplary Claim: 1-3470
DRWN 32 Drawing Page(s)
LN.CNT 12657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 21 OF 83 USPATFULL on STN
AN 2005:215923 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 2005187600 A1 20050825
AI US 2004-998350 A1 20041126 (10)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-3352
DRWN 32 Drawing Page(s)
LN.CNT 14781
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit

scarring that may otherwise occur when the devices are implanted within an animal.

L16 ANSWER 22 OF 83 USPATFULL on STN
AN 2005:215527 USPATFULL
TI Methods and reagents for the treatment of inflammatory disorders
IN Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Manivasakam, Palaniyandi, Brighton, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Slavonic, Michael S., Quincy, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
PI US 2005187203 A1 20050825
AI US 2004-992878 A1 20041119 (10)
PRAI US 2003-524117P 20031121 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2781
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating an immunoinflammatory administering a compound of formula (I), e.g., ibudilast or KC-764, alone or in combination with a corticosteroid, tetra-substituted pyrimidopyrimidine, or other compound. The invention also features pharmaceutical compositions including the combination above for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 23 OF 83 USPATFULL on STN
AN 2005:215524 USPATFULL
TI Methods and reagents for the treatment of inflammatory disorders
IN Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Fong, Jason, Philadelphia, PA, UNITED STATES
Hurst, Nicole, Boston, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Keith, Curtis T., Boston, MA, UNITED STATES
Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES
Sackeyfio, Robyn, Ann Arbor, MI, UNITED STATES
Slavonic, Michael S., Quincy, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Zimmermann, Grant R., Somerville, MA, UNITED STATES
PI US 2005187200 A1 20050825
AI US 2004-987554 A1 20041112 (10)
PRAI US 2003-520446P 20031113 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a tricyclic compound and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing a tricyclic compound and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 24 OF 83 USPATFULL on STN
AN 2005:215464 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005187140 A1 20050825
AI US 2004-408 A1 20041129 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2004-611077P 20040917 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 103
ECL Exemplary Claim: 1-5846
DRWN 32 Drawing Page(s)
LN.CNT 34103
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 25 OF 83 USPATFULL on STN
AN 2005:214574 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005186246 A1 20050825
AI US 2004-6883 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility

FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 101
ECL Exemplary Claim: 1-2606
DRWN 32 Drawing Page(s)
LN.CNT 12658
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 26 OF 83 USPATFULL on STN
AN 2005:214573 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005186245 A1 20050825
AI US 2004-6880 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2785
DRWN 32 Drawing Page(s)
LN.CNT 15059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 27 OF 83 USPATFULL on STN
AN 2005:214572 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005186244 A1 20050825

AI US 2004-1790 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 103
ECL Exemplary Claim: 1-8540
DRWN 32 Drawing Page(s)
LN.CNT 34060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 28 OF 83 USPATFULL on STN
AN 2005:214567 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005186239 A1 20050825
AI US 2004-6897 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-3058
DRWN 32 Drawing Page(s)
LN.CNT 15050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 29 OF 83 USPATFULL on STN

AN 2005:212068 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005183731 A1 20050825
AI US 2004-6908 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1-8061
DRWN 32 Drawing Page(s)
LN.CNT 34032
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L16 ANSWER 30 OF 83 USPATFULL on STN
AN 2005:210011 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005182496 A1 20050818
AI US 2004-6906 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 76
ECL Exemplary Claim: 1-3902
DRWN 32 Drawing Page(s)

LN.CNT 12588
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 31 OF 83 USPATFULL on STN
AN 2005:209984 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 2005182469 A1 20050818
AI US 2004-7837 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 120
ECL Exemplary Claim: 1-2803
DRWN 32 Drawing Page(s)
LN.CNT 14838
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 32 OF 83 USPATFULL on STN
AN 2005:209983 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005182468 A1 20050818
AI US 2004-6891 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1720
DRWN 32 Drawing Page(s)
LN.CNT 14768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 33 OF 83 USPATFULL on STN
AN 2005:209982 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005182467 A1 20050818
AI US 2004-6884 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1168
DRWN 32 Drawing Page(s)
LN.CNT 14785
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 34 OF 83 USPATFULL on STN
AN 2005:209978 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 2005182463 A1 20050818
AI US 2004-1788 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 125
ECL Exemplary Claim: 1-8059
DRWN 32 Drawing Page(s)
LN.CNT 34070
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L16 ANSWER 35 OF 83 USPATFULL on STN
AN 2005:209965 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005182450 A1 20050818
AI US 2004-6890 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-349
DRWN 32 Drawing Page(s)
LN.CNT 14792
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within

an animal.

L16 ANSWER 36 OF 83 USPATFULL on STN
AN 2005:208532 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005181010 A1 20050818
AI US 2004-1789 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 109
ECL Exemplary Claim: 1-296
DRWN 32 Drawing Page(s)
LN.CNT 15014
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 37 OF 83 USPATFULL on STN
AN 2005:208531 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005181009 A1 20050818
AI US 2004-1787 A1 20041201 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 110

ECL Exemplary Claim: 1-570
DRWN 32 Drawing Page(s)
LN.CNT 15035
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 38 OF 83 USPATFULL on STN
AN 2005:208529 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005181007 A1 20050818
AI US 2004-1415 A1 20041130 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 126
ECL Exemplary Claim: 1-444
DRWN 32 Drawing Page(s)
LN.CNT 12675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 39 OF 83 USPATFULL on STN
AN 2005:208527 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)
PI US 2005181005 A1 20050818
AI US 2004-6901 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2510
DRWN 32 Drawing Page(s)
LN.CNT 15035
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 40 OF 83 USPATFULL on STN
AN 2005:205930 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005178396 A1 20050818
AI US 2004-6905 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 50
ECL Exemplary Claim: 1-8063
DRWN 32 Drawing Page(s)
LN.CNT 33965
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L16 ANSWER 41 OF 83 USPATFULL on STN
AN 2005:205929 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005178395 A1 20050818
AI US 2004-6900 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 58
ECL Exemplary Claim: 1-7302
DRWN 32 Drawing Page(s)
LN.CNT 34043
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L16 ANSWER 42 OF 83 USPATFULL on STN
AN 2005:202285 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A.E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005175703 A1 20050811
AI US 2004-6888 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 55
ECL Exemplary Claim: 1-7576
DRWN 32 Drawing Page(s)
LN.CNT 33992
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 43 OF 83 USPATFULL on STN
AN 2005:202247 USPATFULL
TI Polymer compositions and methods for their use
IN Hunter, William L., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
Liggins, Richard T., Coquitlam, CANADA
Takacs-Cox, Aniko, North Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Loss, Troy A. E., North Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005175665 A1 20050811
AI US 2004-6896 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING
PRAI US 2004-611077P 20040917 (60)
US 2004-586861P 20040709 (60)
US 2004-566569P 20040428 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 51
ECL Exemplary Claim: 1-7822
DRWN 32 Drawing Page(s)
LN.CNT 33978
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 44 OF 83 USPATFULL on STN
AN 2005:202246 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005175664 A1 20050811
AI US 2004-4672 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 109
ECL Exemplary Claim: 1-851
DRWN 32 Drawing Page(s)
LN.CNT 15038
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 45 OF 83 USPATFULL on STN
AN 2005:195820 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005169961 A1 20050804
AI US 2004-4675 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 118
ECL Exemplary Claim: 1-1941
DRWN 32 Drawing Page(s)
LN.CNT 15063
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 46 OF 83 USPATFULL on STN
AN 2005:195819 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S.

corporation)
PI US 2005169960 A1 20050804
AI US 2004-4671 A1 20041202 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 110
ECL Exemplary Claim: 1-3328
DRWN 32 Drawing Page(s)
LN.CNT 15057
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 47 OF 83 USPATFULL on STN
AN 2005:182973 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005158356 A1 20050721
AI US 2004-996352 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 117
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 15058
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 48 OF 83 USPATFULL on STN
AN 2005:178293 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vacouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005154374 A1 20050714
AI US 2004-6882 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-2240
DRWN 32 Drawing Page(s)
LN.CNT 15052
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 49 OF 83 USPATFULL on STN
AN 2005:177866 USPATFULL
TI Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
IN Padval, Mahesh, Waltham, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Fong, Jason, Philadelphia, PA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Keith, Curtis, Boston, MA, UNITED STATES
Zimmerman, Grant R., Somervillle, MA, UNITED STATES
Brasher, Bradley B., Natick, MA, UNITED STATES
Sachs, Noah, Boston, MA, UNITED STATES
Chappell, Todd W., Boston, MA, UNITED STATES
PI US 2005153947 A1 20050714
AI US 2004-947455 A1 20040920 (10)
RLI Continuation of Ser. No. US 2004-777517, filed on 12 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-670488, filed on 24 Sep 2003, PENDING
PRAI US 2002-413040P 20020924 (60)
US 2002-417261P 20021009 (60)
US 2002-427424P 20021119 (60)
US 2002-427526P 20021119 (60)
US 2003-464753P 20030423 (60)
DT Utility
FS APPLICATION

LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2921
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 50 OF 83 USPATFULL on STN
AN 2005:176868 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005152948 A1 20050714
AI US 2004-7838 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-2174
DRWN 32 Drawing Page(s)
LN.CNT 12627
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 51 OF 83 USPATFULL on STN
AN 2005:176867 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005152947 A1 20050714
AI US 2004-6903 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-1742
DRWN 32 Drawing Page(s)
LN.CNT 12637
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 52 OF 83 USPATFULL on STN
AN 2005:176866 USPATFULL
TI Implantable sensors and implantable pumps and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005152946 A1 20050714
AI US 2004-6894 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 112
ECL Exemplary Claim: 1-1126
DRWN 32 Drawing Page(s)
LN.CNT 15056
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 53 OF 83 USPATFULL on STN
AN 2005:176865 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005152945 A1 20050714
AI US 2004-6887 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-1310
DRWN 32 Drawing Page(s)
LN.CNT 12592
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 54 OF 83 USPATFULL on STN
AN 2005:176864 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005152944 A1 20050714
AI US 2004-6881 A1 20041207 (11)
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 96
ECL Exemplary Claim: 1-878
DRWN 32 Drawing Page(s)
LN.CNT 12628
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is

placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 55 OF 83 USPATFULL on STN
AN 2005:176861 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005152941 A1 20050714
AI US 2004-996353 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 132
ECL Exemplary Claim: 1
DRWN 32 Drawing Page(s)
LN.CNT 12685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 56 OF 83 USPATFULL on STN
AN 2005:172408 USPATFULL
TI Electrical devices and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005149157 A1 20050707
AI US 2004-996355 A1 20041122 (10)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-525226P 20031124 (60)
US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 111
ECL Exemplary Claim: 1

DRWN 32 Drawing Page(s)
LN.CNT 14769
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 57 OF 83 USPATFULL on STN
AN 2005:164738 USPATFULL
TI Soft tissue implants and anti-scarring agents
IN Hunter, William L., Vancouver, CANADA
Gravett, David M., Vancouver, CANADA
Toleikis, Philip M., Vancouver, CANADA
Maiti, Arpita, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 2005142162 A1 20050630
AI US 2004-1416 A1 20041201 (11)
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)
US 2003-526541P 20031203 (60)
US 2003-524023P 20031120 (60)
US 2003-523908P 20031120 (60)
US 2003-525226P 20031124 (60)
DT Utility
FS APPLICATION
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US
CLMN Number of Claims: 117
ECL Exemplary Claim: 1-4334
DRWN 32 Drawing Page(s)
LN.CNT 12679
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 58 OF 83 USPATFULL on STN
AN 2005:138510 USPATFULL
TI Methods and reagents for the treatment of immunoinflammatory disorders
IN Keith, Curtis, Boston, MA, UNITED STATES
Borisy, Alexis, Arlington, MA, UNITED STATES
Zimmermann, Grant R., Somerville, MA, UNITED STATES
Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Manivasakam, Palaniyandi, Brighton, MA, UNITED STATES
Hurst, Nicole, Boston, MA, UNITED STATES
Foley, Michael A., Chestnut Hill, MA, UNITED STATES
Slavonic, Michael S., Quincy, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
PI US 2005119160 A1 20050602
AI US 2004-966228 A1 20041015 (10)
PRAI US 2003-512415P 20031015 (60)
DT Utility
FS APPLICATION

LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 59 OF 83 USPATFULL on STN
AN 2005:130740 USPATFULL
TI Therapeutic regimens for administering drug combinations
IN Padval, Mahesh, Waltham, MA, UNITED STATES
Elliott, Peter, Marlboro, MA, UNITED STATES
PI US 2005112199 A1 20050526
AI US 2004-947769 A1 20040923 (10)
RLI Continuation-in-part of Ser. No. US 2004-947455, filed on 20 Sep 2004, PENDING Continuation of Ser. No. US 2004-777517, filed on 12 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-670488, filed on 24 Sep 2003, PENDING Continuation-in-part of Ser. No. US 2004-944574, filed on 17 Sep 2004, PENDING Continuation-in-part of Ser. No. US 2004-777518, filed on 12 Feb 2004, PENDING
PRAI US 2003-520446P 20031113 (60)
US 2003-512415P 20031015 (60)
US 2004-557496P 20040330 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1788
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features dosing regimens for the administration of combination therapies, wherein one of the drugs of the combination is formulated for sustained release, or administered repeatedly, and compositions related thereto.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 60 OF 83 USPATFULL on STN
AN 2005:125479 USPATFULL
TI Medical device with multiple coating layers
IN Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard J., Rochester, NY, UNITED STATES
PI US 2005107870 A1 20050519
AI US 2004-923579 A1 20040820 (10)
RLI Continuation-in-part of Ser. No. US 2004-914691, filed on 9 Aug 2004, PENDING Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543,

filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609
DT Utility
FS APPLICATION
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408, US
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN 54 Drawing Page(s)
LN.CNT 18628
AB An implantable medical device that contains two coating layers disposed above at least one of its surfaces. The first coating layer contains a biologically active material; and the second coating layer contains a polymeric material and nanomagnetic material disposed on the first coating layer; the second coating layer is substantially free of the biologically active material. The nanomagentic material has a saturation magentization of from about 2 to about 3000 electromagnetic units per cubic centimeter, and it contains nanomagnetic particleswith an average particle size of less than about 100 nanometers; the average coherence length between adjacent nanomagnetic particles is less than 100 nanometers.

L16 ANSWER 61 OF 83 USPATFULL on STN
AN 2005:92457 USPATFULL
TI Medical device with low magnetic susceptibility
IN Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard J., Rochester, NY, UNITED STATES
Gunderman, Robert D., Honeyoye Falls, NY, UNITED STATES
PI US 2005079132 A1 20050414
AI US 2004-914691 A1 20040809 (10)
RLI Continuation-in-part of Ser. No. US 2004-887521, filed on 7 Jul 2004, PENDING Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, GRANTED, Pat. No. US 6846985 Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609
DT Utility
FS APPLICATION
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408, US
CLMN Number of Claims: 127
ECL Exemplary Claim: 1
DRWN 52 Drawing Page(s)
LN.CNT 17912
AB An assembly with a substrate, nanomagnetic material and magetoresistive material. The nanomagnetic material has a saturation magentization of from about 2 to about 3000 electromagnetic units per cubic centimeter; and it contains nanomagnetic particles with an average particle size of less than about 100 nanometers. The average coherence length between adjacent nanomagnetic particles is less than 100 nanometers.

L16 ANSWER 62 OF 83 USPATFULL on STN
AN 2005:30367 USPATFULL
TI Medical device with low magnetic susceptibility
IN Wang, Xingwu, Wellsville, NY, UNITED STATES

Greenwald, Howard Jay, Rochester, NY, UNITED STATES
PI US 2005025797 A1 20050203
AI US 2004-887521 A1 20040707 (10)
RLI Continuation-in-part of Ser. No. US 2004-867517, filed on 14 Jun 2004, PENDING Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, GRANTED, Pat. No. US 6815609
DT Utility
FS APPLICATION
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408
CLMN Number of Claims: 137
ECL Exemplary Claim: 1
DRWN 42 Drawing Page(s)
LN.CNT 17461
AB An assembly that contains a medical device and biological material within which the medical device is disposed. The assembly has a magnetic susceptibility within the range of plus or minus 1+10.sup.-3 centimeter-gram-seconds

L16 ANSWER 63 OF 83 USPATFULL on STN
AN 2004:321764 USPATFULL
TI Therapeutic assembly
IN Wang, Xingwu, Wellsville, NY, UNITED STATES
Greenwald, Howard J., Rochester, NY, UNITED STATES
Lanzafame, John, Victor, NY, UNITED STATES
Weiner, Michael L., Webster, NY, UNITED STATES
Connelly, Patrick R., Rochester, NY, UNITED STATES
PI US 2004254419 A1 20041216
AI US 2004-867517 A1 20040614 (10)
RLI Continuation-in-part of Ser. No. US 2004-810916, filed on 26 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-808618, filed on 24 Mar 2004, PENDING Continuation-in-part of Ser. No. US 2004-786198, filed on 25 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2004-780045, filed on 17 Feb 2004, PENDING Continuation-in-part of Ser. No. US 2003-747472, filed on 29 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-744543, filed on 22 Dec 2003, PENDING Continuation-in-part of Ser. No. US 2003-409505, filed on 8 Apr 2003, PENDING Continuation-in-part of Ser. No. US 2003-442420, filed on 21 May 2003, PENDING
DT Utility
FS APPLICATION
LREP HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408
CLMN Number of Claims: 175
ECL Exemplary Claim: CLM-1-177
DRWN 40 Drawing Page(s)
LN.CNT 16208
AB A therapeutic assembly that contains a therapeutic agent, a ctyotoxic radioactive material, and a nanomagnetic material with nanomagnetic particles. The nanomagentic particles have an average particle size of less than about 100 nanometers; and the average coherence length between adjacent nanomagnetic particles is less than 100 nanometers. The nanomagnetic material has a saturation magentization of from about 2 to about 3000 electromagnetic units per cubic centimeter, a phase transition temperature of from about 40 to about 200 degrees Celsius,

and a saturation magnetization of from about 2 to about 3,000 electromagnetic units per cubic centimeter

L16 ANSWER 64 OF 83 USPATFULL on STN
AN 2004:292760 USPATFULL
TI Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
IN Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Fong, Jason, Philadelphia, PA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Keith, Curtis, Boston, MA, UNITED STATES
Zimmermann, Grant R., Somerville, MA, UNITED STATES
Brasher, Bradley B., Natick, MA, UNITED STATES
Sachs, Noah, Boston, MA, UNITED STATES
Chappell, Todd W., Boston, MA, UNITED STATES
PI US 2004229849 A1 20041118
AI US 2004-777517 A1 20040212 (10)
RLI Continuation-in-part of Ser. No. US 2003-670488, filed on 24 Sep 2003, PENDING
PRAI US 2002-413040P 20020924 (60)
US 2002-417261P 20021009 (60)
US 2002-427526P 20021119 (60)
US 2002-427424P 20021119 (60)
US 2003-464753P 20030423 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 86
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3245
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 65 OF 83 USPATFULL on STN
AN 2004:286708 USPATFULL
TI Combination therapy for the treatment of immunoinflammatory disorders
IN Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Brasher, Bradley B., Natick, MA, UNITED STATES
Chappell, Todd W., Boston, MA, UNITED STATES
Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES
Sachs, Noah, Boston, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
PI US 2004224876 A1 20041111
AI US 2004-777518 A1 20040212 (10)
PRAI US 2003-447366P 20030214 (60)
US 2003-447412P 20030214 (60)
US 2003-447415P 20030214 (60)
US 2003-447553P 20030214 (60)
US 2003-447648P 20030214 (60)
US 2003-464753P 20030423 (60)

US 2003-503026P 20030915 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 61
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3770
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a non-steroidal immunophilin-dependent immunosuppressant (NsIDI) and an NsIDI enhancer (NsIDIE) or analog or metabolite thereof to the patient. The invention also features a pharmaceutical composition containing an NsIDI and NsIDIE or analog or metabolite thereof for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 66 OF 83 USPATFULL on STN
AN 2004:280852 USPATFULL
TI Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
IN Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Manivasakam, Palaniyandi, W. Roxbury, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Fong, Jason, Philadelphia, PA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Keith, Curtis, Boston, MA, UNITED STATES
Zimmermann, Grant R., Somerville, MA, UNITED STATES
Brasher, Bradley B., Natick, MA, UNITED STATES
Sachs, Noah, Boston, MA, UNITED STATES
Chappell, Todd W., Boston, MA, UNITED STATES
PI US 2004220153 A1 20041104
AI US 2003-670488 A1 20030924 (10)
PRAI US 2002-413040P 20020924 (60)
US 2002-417261P 20021009 (60)
US 2002-427526P 20021119 (60)
US 2003-464753P 20030423 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
CLMN Number of Claims: 77
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3183
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 67 OF 83 USPATFULL on STN
AN 2004:240237 USPATFULL
TI Cytomodulating peptides and methods for treating neurological disorders
IN Iyer, Suhasini, San Ramon, CA, UNITED STATES

Buelow, Roland, Palo Alto, CA, UNITED STATES
Lazarov, Mirella Emilova, Palo Alto, CA, UNITED STATES
Fong, Timothy, Moraga, CA, UNITED STATES
PI US 2004186052 A1 20040923
AI US 2003-693331 A1 20031024 (10)
PRAI US 2002-421297P 20021024 (60)
US 2002-431420P 20021205 (60)
US 2003-470839P 20030515 (60)
DT Utility
FS APPLICATION
LREP DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2528
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods are provided for inhibiting neuronal cell death and the loss of neuronal contacts resulting from acute and chronic neurological disorders, including neurodegenerative and neuroinflammatory diseases. The subject compositions and methods utilize RDP-58 compositions capable of providing a direct neuroprotective effect on neuronal cells in conjunction with the inhibition of autoimmune and inflammatory processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 68 OF 83 USPATFULL on STN
AN 2003:264859 USPATFULL
TI Formulations and methods for providing prolonged local anesthesia
IN Chasin, Mark, Manalapan, NJ, UNITED STATES
Goldenheim, Paul, Wilton, CT, UNITED STATES
Sackler, Richard, Greenwich, CT, UNITED STATES
Tigner, Joseph, New Milford, CT, UNITED STATES
Burch, Ronald M., Wilton, CT, UNITED STATES
PI US 2003185873 A1 20031002
US 6921541 B2 20050726
AI US 2002-237387 A1 20020909 (10)
RLI Continuation of Ser. No. US 2000-522572, filed on 10 Mar 2000, PENDING Continuation of Ser. No. US 1999-342964, filed on 29 Jun 1999, GRANTED, Pat. No. US 6514516 Continuation of Ser. No. US 1997-793861, filed on 16 Jun 1997, GRANTED, Pat. No. US 5942241 Continuation of Ser. No. WO 1996-US10439, filed on 7 Jun 1996, PENDING
PRAI US 1995-105P 19950609 (60)
DT Utility
FS APPLICATION
LREP DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10018
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1630
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 69 OF 83 USPATFULL on STN
AN 2003:257302 USPATFULL
TI Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
IN Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
PI US 2003180352 A1 20030925
AI US 2002-159601 A1 20020530 (10)
RLI Continuation-in-part of Ser. No. US 2001-800593, filed on 6 Mar 2001, PENDING Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363
DT Utility
FS APPLICATION
LREP REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4625
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides, and solubilizers. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides, and solubilizers. The compositions of the present invention can be used for improved delivery of active ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 70 OF 83 USPATFULL on STN
AN 2003:250571 USPATFULL
TI Prolonged anesthesia in joints and body spaces
IN Goldenhim, Paul, Wilton, CT, UNITED STATES
Lacouture, Peter, Newton, CT, UNITED STATES
Donigi-Gale, Donna, Richfield, CT, UNITED STATES
Chasin, Mark, Manalapan, NJ, UNITED STATES
Sackler, Richard, Greenwich, CT, UNITED STATES
PI US 2003175357 A1 20030918
AI US 2003-391242 A1 20030318 (10)
RLI Continuation of Ser. No. US 2001-824465, filed on 2 Apr 2001, GRANTED, Pat. No. US 6534081 Continuation of Ser. No. US 1998-109324, filed on 2 Jul 1998, GRANTED, Pat. No. US 6248345
PRAI US 1997-51601P 19970702 (60)
DT Utility
FS APPLICATION
LREP DAVIDSON, DAVIDSON & KAPPEL, LLC, 15th Floor, 1140 Avenue of the Americas, New York, NY, 10036
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2287
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sustained release local anesthetic formulations are administered intra articularly and/or into body spaces/cavities. The formulation is preferably a plurality of injectable microparticles

including a local anesthetic and an effective amount of a biocompatible, biodegradable, sustained release material prolonging the release of the local anesthetic and optionally and a pharmaceutically acceptable, i.e., non-toxic, augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 71 OF 83 USPATFULL on STN
AN 2003:219347 USPATFULL
TI Local anesthetic, and method of use
IN Chasin, Mark, Manalapan, NJ, UNITED STATES
Buskirk, Glenn Van, Basking Ridge, NJ, UNITED STATES
Maskiewicz, Richard, Ridgefield, CT, UNITED STATES
Ketkar, Amol, Audobon, PA, UNITED STATES
Burton, Kevin, Fishkill, NY, UNITED STATES
Shameem, Mohammed, Nanuet, NY, UNITED STATES
Landau, Craig, Norwalk, CT, UNITED STATES
Coles, Celia, Easton, CT, UNITED STATES
Swanton, Ruth, New Haven, CT, UNITED STATES
Lacouture, Peter, Newton, CT, UNITED STATES
PI US 2003152637 A1 20030814
AI US 2002-57301 A1 20020125 (10)
PRAI US 2001-264186P 20010125 (60)
DT Utility
FS APPLICATION
LREP DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10018
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN 57 Drawing Page(s)
LN.CNT 12597
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to pharmaceutical formulations administered via parenteral methods, which provide a prolonged localized analgesic effect. More particularly, the present invention concerns a pharmaceutically acceptable biocompatible biodegradable carrier containing a local anesthetic and the parenteral administration of such carrier in a manner such that a localized analgesic effect is attained for a prolonged period of time.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 72 OF 83 USPATFULL on STN
AN 2003:53538 USPATFULL
TI Formulations and methods for providing prolonged local anesthesia
IN Goldenheim, Paul, Wilton, CT, United States
Chasin, Mark, Manalapan, NJ, United States
Sackler, Richard, Greenwich, CT, United States
Burch, Ronald M., Wilton, CT, United States
Tigner, Joseph, New Milford, CT, United States
PA Euro-Celtique, S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)
PI US 6524607 B1 20030225
AI US 2000-523361 20000310 (9)
RLI Continuation of Ser. No. US 1999-342964, filed on 29 Jun 1999
Continuation of Ser. No. US 793861, now patented, Pat. No. US 5942241, issued on 27 Dec 1996
PRAI US 1995-105P 19950609 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Levy, Neil S.
LREP Davidson, Davidson & Kappel, LLC
CLMN Number of Claims: 1

ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1511
AB A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

L16 ANSWER 73 OF 83 USPATFULL on STN
AN 2003:47532 USPATFULL
TI Formulations and methods for providing prolonged local anesthesia
IN Chasin, Mark, Manalapan, NJ, United States
Sackler, Richard, Greenwich, CT, United States
Burch, Ronald M., Wilton, CT, United States
Goldenheim, Paul, Wilton, CT, United States
Tigner, Joseph, New Milford, CT, United States
PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)
PI US 6521259 B1 20030218
AI US 2000-523360 20000310 (9)
RLI Continuation of Ser. No. US 1999-342964, filed on 29 Jun 1999
Continuation of Ser. No. US 793861, now patented, Pat. No. US 5942241
PRAI US 1995-105P 19950609 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Levy, Neil S.
LREP Davidson, Davidson & Kappel, LLC
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1759
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when inplanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 74 OF 83 USPATFULL on STN
AN 2003:33185 USPATFULL
TI Formulations and methods for providing prolonged local anesthesia
IN Chasin, Mark, Manalapan, NJ, United States
Sackler, Richard, Greenwich, CT, United States
Burch, Ronald M., Wilton, CT, United States
Goldenheim, Paul, Wilton, CT, United States
Tigner, Joseph, New Milford, CT, United States
PA Euro-Celtique, S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)
PI US 6514516 B1 20030204
AI US 1999-342964 19990629 (9)
RLI Continuation of Ser. No. US 793861, now patented, Pat. No. US 5942241
PRAI US 1995-105P 19950609 (60)

DT Utility
FS GRANTED
EXNAM Primary Examiner: Levy, Neil S.
LREP Davidson, Davidson & Kappel, LLC
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1802
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 75 OF 83 USPATFULL on STN
AN 2002:238665 USPATFULL
TI Formulations and methods for providing prolonged local anesthesia
IN Goldenheim, Paul, Wilton, CT, United States
Donigi-Gale, Donna, Richfield, CT, United States
Burton, Kevin, Fishkill, NY, United States
Shameem, Mohammed, Elmsford, NY, United States
Ketkar, Amol, Elmsford, NY, United States
Chasin, Mark, Manalapan, NJ, United States
Maskiewicz, Richard, Ridgefield, CT, United States
PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)
PI US 6451335 B1 20020917
AI US 1998-109323 19980702 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Davidson, Davidson & Kappel, LLC
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a non-toxic augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent. In preferred embodiments, the controlled release material is a low molecular weight, acid-terminated polymer. A further aspect of the invention is directed to such formulations which release the local anesthetic in two phases, the first a rapid "bolus" to initiate anesthesia and a second, slower release to maintain anesthesia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 76 OF 83 USPATFULL on STN
AN 2002:105713 USPATFULL
TI Prolonged anesthesia in joints and body spaces
IN Goldenheim, Paul, Wilton, CT, UNITED STATES

Lacouture, Peter, Newton, CT, UNITED STATES
Donigi-Gale, Donna, Richfield, CT, UNITED STATES
Chasin, Mark, Manalapan, NJ, UNITED STATES
Sackler, Richard, Greenwich, CT, UNITED STATES
PI US 2002054915 A1 20020509
US 6534081 B2 20030318
AI US 2001-824465 A1 20010402 (9)
RLI Continuation of Ser. No. US 1998-109324, filed on 2 Jul 1998, GRANTED, Pat. No. US 6248345
PRAI US 1997-51601P 19970702 (60)
DT Utility
FS APPLICATION
LREP DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 Seventh Avenue - 14th Floor, New York, NY, 10018
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 2285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sustained release local anesthetic formulations are administered intra articularly and/or into body spaces/cavities. The formulation is preferably a plurality of injectable microparticles including a local anesthetic and an effective amount of a biocompatible, biodegradable, sustained release material prolonging the release of the local anesthetic and optionally and a pharmaceutically acceptable, i.e., non-toxic, augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 77 OF 83 USPATFULL on STN
AN 2001:93113 USPATFULL
TI Prolonged anesthesia in joints and body spaces
IN Goldenheim, Paul, Wilton, CT, United States
Lacouture, Peter, Newton, CT, United States
Donigi-Gale, Donna, Richfield, CT, United States
Chasin, Mark, Manalapan, NJ, United States
Sackler, Richard, Greenwich, CT, United States
PA Euro-Celtique, S.A., Luxembourg, Luxembourg (non-U.S. corporation)
PI US 6248345 B1 20010619
AI US 1998-109324 19980702 (9)
PRAI US 1997-51601P 19970702 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Davidson, Davidson, & Kappel, LLC.
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 2562
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sustained release local anesthetic formulations are administered intra articularly and/or into body spaces/cavities. The formulation is preferably a plurality of injectable microparticles including a local anesthetic and an effective amount of a biocompatible, biodegradable, sustained release material prolonging the release of the local anesthetic and optionally and a pharmaceutically acceptable, i.e., non-toxic, augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 78 OF 83 USPATFULL on STN
AN 2001:78729 USPATFULL
TI High load formulations and methods for providing prolonged local anesthesia
IN Berde, Charles B., Brookline, MA, United States
Langer, Robert S., Newton, MA, United States
Curley, Joanne, San Jose, CA, United States
Castillo, Jenny, Philadelphia, PA, United States
PA Children's Medical Center Corp., Boston, MA, United States (U.S. corporation)
PI US 6238702 B1 20010529
AI US 1999-352511 19990712 (9)
RLI Continuation of Ser. No. US 1996-714782, filed on 16 Sep 1996, now patented, Pat. No. US 5922340 Continuation-in-part of Ser. No. US 1995-432402, filed on 1 May 1995, now patented, Pat. No. US 5700485 Continuation-in-part of Ser. No. US 1993-119958, filed on 10 Sep 1993, now patented, Pat. No. US 5618563 Continuation-in-part of Ser. No. US 1992-943287, filed on 10 Sep 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Spear, James M.; Assistant Examiner: Bennett, Rachel M
LREP Davidson, Davidson & Kappel, LLC
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 2024
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation for inducing sustained local anesthesia in a patient comprising a substrate comprising a high load of local anesthetic by weight and an effective amount of a biocompatible, controlled release material to obtain a. reversible nerve blockade or anesthesia effect when implanted or injected in a patient, and a non-toxic glucocorticosteroid agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the glucocorticosteroid agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 79 OF 83 USPATFULL on STN
AN 1999:99389 USPATFULL
TI Formulations and methods for providing prolonged local anesthesia
IN Chasin, Mark, Manalapan, NJ, United States
Sackler, Richard, Greenwich, CT, United States
Burch, Ronald M., Wilton, CT, United States
Goldenheim, Paul, Wilton, CT, United States
Tigner, Joseph, New Milford, CT, United States
PA Euro-Celtique, S.A., Luxembourg, Luxembourg (non-U.S. corporation)
PI US 5942241 19990824
WO 9641616 19961227
AI US 1997-793861 19970616 (8)
WO 1996-US10439 19960607
19970616 PCT 371 date
19970616 PCT 102(e) date
PRAI WO 1995-60000105 19950609
DT Utility
FS Granted
EXNAM Primary Examiner: Levy, Neil S.
LREP Davidson, Davidson & Kappel, LLC
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1918
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation and methods for inducing sustained regional local

anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 80 OF 83 USPATFULL on STN
AN 1999:78347 USPATFULL
TI High load formulations and methods for providing prolonged local anesthesia
IN Berde, Charles B., Brookline, MA, United States
Langer, Robert S., Newton, MA, United States
Curley, Joanne, San Jose, CA, United States
Castillo, Jenny, Philadelphia, PA, United States
PA Children's Medical Center Corporation, Boston, MA, United States (U.S. corporation)
PI US 5922340 19990713
AI US 1996-714782 19960916 (8)
RLI Continuation-in-part of Ser. No. US 1995-432402, filed on 5 May 1995, now patented, Pat. No. US 5700485 which is a continuation-in-part of Ser. No. US 1993-119958, filed on 10 Sep 1993, now patented, Pat. No. US 5618563 which is a continuation-in-part of Ser. No. US 1992-943287, filed on 10 Sep 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Kulkosky, Peter F.
LREP Davidson, Davidson & Kappel, LLC
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 2066
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation for inducing sustained local anesthesia in a patient comprising a substrate comprising a high load of local anesthetic by weight and an effective amount of a biocompatible, controlled release material to obtain a reversible nerve blockade or anesthesia effect when implanted or injected in a patient, and a non-toxic glucocorticosteroid agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the glucocorticosteroid agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 81 OF 83 USPAT2 on STN
AN 2005:318834 USPAT2
TI Compositions and methods for treating diverticular disease
IN Hunter, William L, Vancouver, CANADA
Toleikis, Philip M, Vancouver, CANADA
Gravett, David M, Vancouver, CANADA
Avelar, Rui, Vancouver, CANADA
Guan, Dechi, Vancouver, CANADA
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)
PI US 7241736 B2 20070710
AI US 2005-129763 20050512 (11)
RLI Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING
PRAI US 2004-586861P 20040709 (60)
US 2004-578471P 20040609 (60)

PRAI US 2003-523908P 20031120 (60)
US 2003-524023P 20031120 (60)
US 2003-518785P 20031110 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Monshipouri, Maryam; Assistant Examiner: Tsay, Marsha
LREP Seed IP Law Group PLLC
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 15 Drawing Page(s)
LN.CNT 18529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Agents, compositions, and implants are provided herein for treating diverticular disease (e.g., diverticulosis and diverticulitis). In particular, fibrosis-inducing agents, hemostatic agents, and/or anti-infective agents, or compositions containing one or more of these agents are provided for use in methods for treating diverticular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 82 OF 83 USPAT2 on STN
AN 2003:264859 USPAT2
TI Formulations and methods for providing prolonged local anesthesia
IN Chasin, Mark, Manalapan, NJ, UNITED STATES
Goldenheim, Paul, Wilton, CT, UNITED STATES
Sackler, Richard, Greenwich, CT, UNITED STATES
Tigner, Joseph, New Milford, CT, UNITED STATES
Burch, Ronald M, Wilton, CT, UNITED STATES
PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)
PI US 6921541 B2 20050726
AI US 2002-237387 20020909 (10)
RLI Continuation of Ser. No. US 2000-522572, filed on 10 Mar 2000, ABANDONED Continuation of Ser. No. US 1999-342964, filed on 29 Jun 1999, Pat. No. US 6514516 Continuation of Ser. No. US 793861, Pat. No. US 5942241 A 371 of International Ser. No. WO 1996-US10439, filed on 7 Jun 1996
PRAI US 1995-105P 19950609 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Levy, Neil S.
LREP Davidson, Davidson & Kappel, LLC
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1858
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 83 OF 83 USPAT2 on STN
AN 2002:105713 USPAT2
TI Prolonged anesthesia in joints and body spaces
IN Goldenheim, Paul, Wilton, CT, United States
Donigi-Gale, Donna, Richfield, CT, United States

Sackler, Richard, Greenwich, CT, United States
Lacouture, Peter, Newton, CT, United States
Chasin, Mark, Manalapan, NJ, United States
PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)
PI US 6534081 B2 20030318
AI US 2001-824465 20010402 (9)
RLI Continuation of Ser. No. US 1998-109324, filed on 2 Jul 1998, now patented, Pat. No. US 6248345
PRAI US 1997-51601P 19970702 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Azpuru, Carlos
LREP Davidson, Davidson & Kappel, LLC
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 2596
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sustained release local anesthetic formulations are administered intra articularly and/or into body spaces/cavities. The formulation is preferably a plurality of injectable microparticles including a local anesthetic and an effective amount of a biocompatible, biodegradable, sustained release material prolonging the release of the local anesthetic and optionally and a pharmaceutically acceptable, i.e., non-toxic, augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable without the augmenting agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	420.33	420.96

FILE 'CAPLUS' ENTERED AT 11:52:04 ON 20 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Jul 2007 VOL 147 ISS 5
FILE LAST UPDATED: 19 Jul 2007 (20070719/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s Jin Tuo/AU
L17 36 JIN TUO/AU

=> s l17 and encapsul?

```
         68019 ENCAPSUL?
L18          2 L17 AND ENCAPSUL?

=> dis l18 1-2 bib abs

L18  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:257414  CAPLUS
DN   146:302401
TI   Polysaccharide microparticles containing biological agents
IN   Jin, Tuo; Wu, Fei; Yuan, Weien
PA   Peop. Rep. China
SO   PCT Int. Appl., 47pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2007025441         A1    20070308    WO 2006-CN1777          20060720
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
             KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
             MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
             SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
             US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRAI US 2005-712548P       P     20050829
AB   This invention relates to method of preparing polysaccharide glassy
     microparticles which are less than 10μm in diameter and contain
     structurally delicate agents, such as proteins, peptides, gene materials,
     vaccines, antibodies, viruses and liposomes using low-temperature
aqueous-aqueous
     emulsification (free of polyelectrolytes) and freezing-induced phase separation
     When delicate agents are added to a polysaccharide-PEG two phase system
     followed by homogenization (or other shear adding process), the agents
     partition into the polysaccharide dispersed phase preferentially.  These
     processes help to avoid aggregation of proteins caused by interaction with
     charged polyelectrolytes used for stabilizing the polysaccharide dispersed
     phase in our previously reported aqueous-aqueous emulsion.  When this system is
     frozen and lyophilized, glassy particles less than 10μm in diameter containing
     delicate agents can be formed.  These fine polysaccharide particles
     protect proteins within their hydrophilic glassy matrix, and can therefore
     be easily suspended in hydrophobic polymer solns. and formulated to
     various forms of sustained release devices such as microsphere, sheets,
     fibers, coating layers, and scaffolds.  The particles can also be
     dispersed in hydrophilic gels to improve releasing kinetics and to deliver
     vaccines and antibodies for immune therapy.  For example, fairly stable
     aqueous-aqueous emulsion was prepared by simply mixing dextran solution
(containing 2
     weight/weight% myoglobin) 10% with PEG solution 10% at 0-4°C.  A small mol.
     sugar, trehalose 1% was added in the dextran solution for lyophilization and
     stored in refrigerator for 1 h.  The sample was removed from the
     refrigerator and images were quickly taken before the dispersed phase
     fuses at elevated temperature  The size of the dispersed dextran phase (the
     droplets) ranged between 3-7 μm in diameter  This emulsion sample was then
     frozen at -20 0C, followed by lyophilization and dichloromethane-washing
     to remove the continuous PEG phase.  The size reduction from 3-7 to 1-3 μm
     by lyophilization was due to dehydration.
RE.CNT  6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
```

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:971951 CAPLUS
DN 140:19881
TI Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion
IN Jin, Tuo; Zhu, Hua; Zhu, Jiahao
PA Peop. Rep. China
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101600	A2	20031211	WO 2003-CN431	20030603
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003059402	A1	20030327	US 2002-291327	20021108
	US 6998393	B2	20060214		
	CA 2487867	A1	20031211	CA 2003-2487867	20030603
	AU 2003245804	A1	20031219	AU 2003-245804	20030603
	EP 1572341	A2	20050914	EP 2003-737838	20030603
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006504636	T	20060209	JP 2004-508943	20030603
	US 2006121121	A1	20060608	US 2006-517122	20060126
PRAI	US 2002-384971P	P	20020603		
	US 2002-418100P	P	20021011		
	US 2002-291327	A	20021108		
	US 2000-214037P	P	20000623		
	US 2001-886555	A	20010621		
	WO 2001-CN1033	W	20010622		
	WO 2003-CN431	W	20030603		

AB This invention provides method for sustained release delivery of structurally delicate agents such as proteins and peptides. Using a unique emulsion system (stable polymer aqueous-aqueous emulsion), proteins and peptides can be microencapsulated in polysaccharide glassy particles under a condition free of any chemical or phys. hazard such as organic solvents, strong interfacial tension, strong shears, elevated temperature, large amount of surfactants, and crosslinking agents. Proteins loaded in these glassy particles showed strong resistance to organic solvents, prolonged activity in hydrated state, and an excellent sustained release profile with minimal burst and incomplete release when being further loaded in degradable polymer microspheres. This invention provides a simple yet effective approach to address all the tech. challenges raised in sustained release delivery of proteins.

=> s Zhu Hua/AU
L19 198 ZHU HUA/AU

=> s l19 and encapsul?
68019 ENCAPSUL?

```
L20          1 L19 AND ENCAPSUL?

=> dis l20 bib abs

L20  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2003:971951  CAPLUS
DN   140:19881
TI   Hazard-free microencapsulation for structurally delicate agents, an
     application of stable aqueous-aqueous emulsion
IN   Jin, Tuo; Zhu, Hua; Zhu, Jiahao
PA   Peop. Rep. China
SO   PCT Int. Appl., 49 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
PI   WO 2003101600         A2    20031211    WO 2003-CN431            20030603
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2003059402          A1    20030327    US 2002-291327           20021108
     US 6998393             B2    20060214
     CA 2487867             A1    20031211    CA 2003-2487867          20030603
     AU 2003245804          A1    20031219    AU 2003-245804           20030603
     EP 1572341             A2    20050914    EP 2003-737838           20030603
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2006504636          T     20060209    JP 2004-508943           20030603
     US 2006121121          A1    20060608    US 2006-517122           20060126
PRAI US 2002-384971P        P     20020603
     US 2002-418100P        P     20021011
     US 2002-291327         A     20021108
     US 2000-214037P        P     20000623
     US 2001-886555         A     20010621
     WO 2001-CN1033         W     20010622
     WO 2003-CN431          W     20030603
AB   This invention provides method for sustained release delivery of
     structurally delicate agents such as proteins and peptides.  Using a
     unique emulsion system (stable polymer aqueous-aqueous emulsion), proteins and
     peptides can be microencapsulated in polysaccharide glassy particles under
     a condition free of any chemical or phys. hazard such as organic solvents,
     strong interfacial tension, strong shears, elevated temperature, large amount
of
     surfactants, and crosslinking agents.  Proteins loaded in these glassy
     particles showed strong resistance to organic solvents, prolonged activity in
     hydrated state, and an excellent sustained release profile with minimal
     burst and incomplete release when being further loaded in degradable
     polymer microspheres.  This invention provides a simple yet effective
     approach to address all the tech. challenges raised in sustained release
     delivery of proteins.


=> s Zhu Jiahao/AU
L21          4 ZHU JIAHAO/AU
```

=> dis l21 1-4 bib abs

L21 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:304352 CAPLUS
DN 145:59548
TI Phylogenetics of the common pearl oysters in the genus Pinctada: evidence from nrDNA ITS sequence
AU Yu, Dahui; Zhu, Jiahao
CS South China Sea Fisheries Research Institute, Chinese Academy of Fishery Sciences, Guangzhou, Guangdong Province, 510300, Peop. Rep. China
SO Shengwu Duoyangxing (2005), 13(4), 315-323
CODEN: SHDUEM; ISSN: 1005-0094
PB Kexue Chubanshe
DT Journal
LA Chinese
AB Some species in the genus Pinctada are important resources for the pearl industry, but some of them are on the verge of extinction. The evolutionary relationship and identification some species in Pinctada were studied based on sequences of the internal transcribed spacers (ITS1 and ITS2) of nuclear ribosomal DNA (nrDNA). The length of ITS1 ranges 410-482 bp, with P. margaritifera and P. maxima being the longest, and P. fucata, P. fucata martensii, P. imbricata, and P. nigra the shortest. The length of ITS2 ranges 210-249 bp, with P. albina and P. nigra being the longest, and P. margaritifera and P. maxima the shortest. Homogeneity test on the pattern of nucleotide substitution indicates that the GC contents in P. margaritifera and P. maxima are significantly higher, and chromosomal rearrangements may have occurred in P. chemnitzi. This finding suggests that P. margaritifera and P. maxima are likely to be primitive species and P. chemnitzi appears to be a recent species. Phylogenetic anal. shows that the pearly oysters studied constitute 3 clades: clade I with P. fucata, P. fucata martensii, and P. imbricata; clade II with P. albina, P. nigra, P. chemnitzi, and P. radiata; and clade III with P. margaritifera and P. maxima. The insignificant genetic differentiation among the species in clade I indicate that they may be conspecific, with P. imbricata being the senior synonym. In clade II, the low genetic divergence between P. albina and P. nigra suggests that they may represent 2 subspecies. The ITS1 sequence of P. radiata in GenBank is almost identical to that of P. chemnitzi as determined in the present study, and thus we suspect that the specimen used for the P. radiata sequence in GenBank was misidentified. Clade III has a basal position, suggesting that species in this clade are more primitive than the others. This is congruent with the results revealed by the homogeneity test on the nucleotide substitution pattern.

L21 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:21392 CAPLUS
DN 145:206746
TI Studies on genetic relationships between Haliotis Diversicolor and H. Discus using AFLP fingerprinting and DNA sequence analysis
AU Wang, Zhiyong; Ke, Caihuan; Wang, Yilei; He, Jiaqi; Zhu, Jiahao
CS Fisheries College, Jimei University, Xiamen, 361021, Peop. Rep. China
SO Gaojishu Tongxun (2004), 14(12), 93-98
CODEN: GTONE8; ISSN: 1002-0470
PB Gaojishu Tongxun Zazhishe
DT Journal
LA Chinese
AB Haliotis diversicolor and Haliotis discus are economically important abalone species in southern and northern China, resp. There are different opinions on systematic relationship between the two subspecies of H. discus and, particularly, of H. diversicolor. The aim of this study was to elucidate the genetic differences between the two species and their subspecies based on AFLP (Amplified Fragment Length Polymorphism) technol., sequence analyses of nuclear DNA [first internal transcribed spacer of rRNA (ITS-1) and 18S rRNA] and mitochondrial DNA [16S rRNA and

cytochrome oxidase I (COI) gene]. The results indicated that the genetic divergence between H. diversicolor diversicolor and H. diversicolor supertexta is small, probably only representing differences at the population level. Yet H. discus discus and H. discus hannai are genetically distinct based on AFLP fingerprinting pattern, thus justifying their subspecies status. AFLP technique was shown to be a simple, fast, highly reproducible, and thus a useful tool for evaluating genus identity and genetic diversity of abalone.

L21 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:101739 CAPLUS
DN 140:353814
TI A mini-review of studies on genetic basis of sex determination in fish
AU Tong, Jingou; Zhu, Jiahao; Guan, Haishan
CS Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, Hubei Province, 430072, Peop. Rep. China
SO Shuichan Xuebao (2003), 27(2), 169-176
CODEN: SHXUEK; ISSN: 1000-0615
PB Shuichan Xuebao Bianweihui
DT Journal; General Review
LA Chinese
AB A review. The authors discuss the progress in the past few decades in both cytogenetic and mol. genetic studies on sex determination in fish. The prospects, significance, and possible future directions of the studies on fish sex determination are also discussed.

L21 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:971951 CAPLUS
DN 140:19881
TI Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion
IN Jin, Tuo; Zhu, Hua; Zhu, Jiahao
PA Peop. Rep. China
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101600	A2	20031211	WO 2003-CN431	20030603
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003059402	A1	20030327	US 2002-291327	20021108
	US 6998393	B2	20060214		
	CA 2487867	A1	20031211	CA 2003-2487867	20030603
	AU 2003245804	A1	20031219	AU 2003-245804	20030603
	EP 1572341	A2	20050914	EP 2003-737838	20030603
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006504636	T	20060209	JP 2004-508943	20030603
	US 2006121121	A1	20060608	US 2006-517122	20060126
PRAI	US 2002-384971P	P	20020603		
	US 2002-418100P	P	20021011		
	US 2002-291327	A	20021108		
	US 2000-214037P	P	20000623		

US 2001-886555 A 20010621
WO 2001-CN1033 W 20010622
WO 2003-CN431 W 20030603

AB This invention provides method for sustained release delivery of structurally delicate agents such as proteins and peptides. Using a unique emulsion system (stable polymer aqueous-aqueous emulsion), proteins and peptides can be microencapsulated in polysaccharide glassy particles under a condition free of any chemical or phys. hazard such as organic solvents, strong interfacial tension, strong shears, elevated temperature, large amount of surfactants, and crosslinking agents. Proteins loaded in these glassy particles showed strong resistance to organic solvents, prolonged activity in hydrated state, and an excellent sustained release profile with minimal burst and incomplete release when being further loaded in degradable polymer microspheres. This invention provides a simple yet effective approach to address all the tech. challenges raised in sustained release delivery of proteins.

=> dis hist

(FILE 'HOME' ENTERED AT 11:18:20 ON 20 JUL 2007)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT, NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPIFV, WPINDEX, WSCA, WTEXTILES, EMBASE, MEDLINE, BIOSIS' ENTERED AT 11:20:12 ON 20 JUL 2007

L1 7433789 S COMPOSITION
L2 554816 S L1 AND (POLYSACHARIDE OR DEXTRAN OR STARCH OR CELLULOSE)
L3 8 S L2 AND ECAPSUL?
L4 69931 S L2 AND ENCAPSUL?
L5 55983 S L4 AND (EPO OR ERYTHROPOIETIN OR CSF OR TPA OR INTERFERON O
L6 20251 S L5 AND (PEG OR PEO OR PVP OR PVA)
L7 0 S L6 AND (SOLID(A)OIL(A)WATER(A)EMULSION)
L8 20192 S L6 AND (METHOD OR PROCESS)
L9 16 S L8 AND (PARTICLES(W)DIAMETER)
L10 7614 S L6 AND MICROSPHERE
L11 1444 S L10 AND CHITOSAN
L12 1338 S L11 AND DRUG
L13 405 S L12 AND (PREDNISOLONE OR CORTISONE)
L14 236 S L13 AND (CELLULOSE(A)ACETATE)
L15 181 S L14 AND (SUSTAINED(A)RELEASE)
L16 83 S L15 AND (AQUEOUS(W) SUSPENSION)

FILE 'CAPLUS' ENTERED AT 11:52:04 ON 20 JUL 2007
L17 36 S JIN TUO/AU
L18 2 S L17 AND ENCAPSUL?
L19 198 S ZHU HUA/AU
L20 1 S L19 AND ENCAPSUL?
L21 4 S ZHU JIAHAO/AU